| Name | N4 Pharma |
|---|---|
| Epic | N4P |
| Isin | GB00BYW8QM32 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 0.69p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £2.72 | Debt ratio | n/a |
| Shares in issue | 394.78 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -125.77 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -0.52 | 52-week high / low | 0.50p / 3.07p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | N4 Pharma |
|---|---|
| Address | 6th Floor, 60 Gracechurch Street, London, United Kingdom, EC3V 0HR |
| Telephone | |
| Website | http://www.n4pharma.com/ |
| Director | Position |
|---|---|
| Mr Nigel Theobald | CEO |
| Mr David Templeton | Executive Director |
| Mr Luke Cairns | Executive Director |
| Dr Chris Britten | Non-Executive Chairman |
| Mr Michael Palfreyman | Vice Chairman and CEO |
| Assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/12/23 | 31/12/22 | 31/12/21 |
| Intangible asssets and goodwill | 0.06 | n/a | n/a |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 0.06 | n/a | n/a |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 0.19 | 0.25 | 0.56 |
| Cash and equivalents | 1.03 | 1.92 | 1.78 |
| Other current assets and asset held for resale | n/a | n/a | n/a |
| Total of all assets | 1.27 | 2.17 | 2.34 |
| Liabilities £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 0.08 | -0.08 | 0.21 |
| Long term liabilities | n/a | n/a | n/a |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 0.08 | -0.08 | 0.21 |
| Net assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 1.19 | 2.24 | 2.13 |
| Equity £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 9.35 | 9.21 | 9 |
| Minority interests | 0.07 | n/a | n/a |
| Retained earnings | -9.34 | -8.06 | -7.03 |
| Share premium account | 14.87 | 14.7 | 13.95 |
| Total equity | 1.19 | 2.24 | 2.13 |
| Income £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -1.43 | -1.19 | -1.84 |
| Pre-tax profit | -1.43 | -1.19 | -1.84 |